MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

5.395 -0.025 (-0.46%)
Streaming Delayed Price Updated: 1:27 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
Ardelyx Eyes $500M+ Revenue as IBSRELA Growth Puts Profitability Within Reach ↗
Ardelyx (NASDAQ:ARDX) executives said at the Jefferies Global Healthcare Conference that the company is focused on expanding demand for its commercial products, IBSRELA and XPHOZAH, while continuing to... 
Via MarketBeat
News headline image
Ardelyx to Participate at the Jefferies Global Healthcare Conference 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical Meetings
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx (ARDX) Q1 2026 Earnings Transcript ↗
Ardelyx (ARDX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
Ardelyx Inc (NASDAQ:ARDX) Reports Strong Q1 Revenue Beat as IBSRELA Momentum Accelerates ↗
Via Chartmill
Ardelyx Inc (NASDAQ:ARDX) Reports Q4 2025 Revenue Beat but EPS Miss, Shares Fall ↗
Via Chartmill
Ardelyx Stock Rises Premarket As Piper Sees Over 100% Upside — Says Constipation Drug ‘Stole The Show’ With 2026 Guidance ↗
Via Stocktwits
News headline image
Ardelyx Reports First Quarter 2026 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical Meetings
Presentation evaluates the long-term impact of XPHOZAH® on serum electrolytes and select nutrition biomarkers 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx President and CEO Sells 41,000 Shares for $243,000 ↗
This biotech innovator in gastrointestinal and kidney therapies reported a notable insider sale amid routine portfolio adjustments. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Award recognizes leading chronic kidney disease advocates 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C
Post hoc analysis supports a reduction of time to first bowel movement and a consistent improvement in abdominal symptoms, including pain, discomfort, and bloating, during 12 weeks of treatment 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Participate in Upcoming Investor Conferences
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership ↗
Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions
First-of-its-kind partnership designed to educate and mobilize patients to imagine a healthier tomorrow 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
ARDX Stock Jumps Over 5% Overnight As Director Loads Up In Vote Of Confidence For Flagship Constipation Drug ↗
On Monday, Wedbush maintained its $19 price target on Ardelyx shares, implying a 230% upside from current levels. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
News headline image
ARDX Stock Is Down Pre-Market After Q4 Earnings Miss, So Why Did This Firm Just Hike Price Target By 80%? ↗
Analysts at H.C. Wainwright hiked their price target for Ardelyx shares to $18 from $10. 
Via Stocktwits
Topics Earnings Intellectual Property
News headline image
ARDX Stock Slips After Hours As Q4 Earnings Disappoint: Retail Sees Ibsrela Driving Outperformance In Time ↗
The company reported no earnings for the fourth quarter, compared to an analyst estimate of $0.01 per share. 
Via Stocktwits
Topics Artificial Intelligence
News headline image
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Conference call scheduled for 4:30 p.m. Eastern Time 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Ardelyx Receives New Patent for Tenapanor
New patent covers IBSRELA® and XPHOZAH® and expires in 2042 
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
From Ardelyx, Inc.
Via GlobeNewswire
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Ardelyx Stock Is Rallying – What Is Making Retail So Bullish? ↗
The company said it made significant commercial progress in 2025, generating approximately $378 million in product revenue. 
Via Stocktwits
News headline image
Ardelyx Reports Preliminary 2025 Revenue and Provides 2026 Strategic Outlook
From Ardelyx, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story